SCHEMBL4331238

SCHEMBL4331238

COc1ccc(NC(=O)c2nc(CN3CCS(O)(O)CC3)c3ccccn23)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.50
CNR2 P34972 4/20 0.50
RAB9A P51151 4/20 0.41
NPC1 O15118 2/20 0.41
PABPC1 P11940 3/20 0.41
LMNA P02545 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
OPRM1 P35372 2/20 0.41
OPRD1 P41143 2/20 0.41
OPRK1 P41145 2/20 0.41
OGFRL1 Q5TC84 2/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
KMT2A Q03164 5/20 0.40
MEN1 O00255 4/20 0.40
POLB P06746 2/20 0.40
ALDH1A1 P00352 1/20 0.40
INSR P06213 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4331219 0.93 CNR1 (0.58) CNR1CNR2RAB9ANPC1PABPC1
SCHEMBL4341823 0.83 CNR1 (0.54) CNR1CNR2RAB9ANPC1LMNA
SCHEMBL4320289 0.82 CNR1 (0.49) CNR1CNR2KMT2AMEN1KDM4E
SCHEMBL4333588 0.81 CNR1 (0.52) CNR1CNR2
SCHEMBL4334584 0.81 CNR2 (0.57) CNR1CNR2RAB9ANPC1LMNA
SCHEMBL4333051 0.80 CNR1 (0.56) CNR1CNR2RAB9ANPC1LMNA
SCHEMBL4327319 0.79 CNR2 (0.54) CNR1CNR2ALDH1A1
SCHEMBL4327706 0.79 CNR1 (0.62) CNR1CNR2RAB9ANPC1KMT2A
SCHEMBL4326981 0.79 CNR1 (0.55) CNR1CNR2RAB9ANPC1LMNA
SCHEMBL13578118 0.79 CNR1 (0.62) CNR1CNR2RAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES MERCK & CO., INC. 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES CNR2, CNR1, TRPV1 CNR1 2/4885CNR2 1/4885RAB9A 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.